Latest Chronic obstructive pulmonary disease Stories
LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium)
- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF)
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc.
Lung Institute Provides Lung Disease Sufferers Advice to Avoid a Flare-Up During Allergy Season (PRWEB) April 24, 2014 To the majority of the population,
American Lung Association in Washington & Aljoya Thornton Place Hold Respiratory Rally to Educate Residents, Friends & Neighbors about Caring for Those with Respiratory Challenges.
Each of the Emerging LABA/LAMA Fixed-Dose Combinations Has Advantages Over Current Therapies on Efficacy Measures, According to Findings from Decision Resources Group BURLINGTON, Mass., April
For the fourth consecutive year, Austin-based Alen Corporation will have a significant presence at the American Lung Association’s (ALA) Fight for Air Climb, taking place April 26 at the Frost
New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com.
DALLAS, April 19, 2014 /PRNewswire/ -- ReportsnReports.com offers COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014 to 2018 industry research report in
A group of drugs commonly prescribed for insomnia, anxiety and breathing issues "significantly increase the risk" that older people with chronic obstructive pulmonary disease, or COPD, need to visit a doctor or Emergency Department for respiratory reasons, new research has found.
- To give a box on the ear to.